Center for Scientific Review; Notice of Closed Meetings, 37641-37642 [2015-16063]
Download as PDF
Federal Register / Vol. 80, No. 126 / Wednesday, July 1, 2015 / Notices
In
accordance with Public Law 105–392,
the ACMH was established to provide
advice to the Deputy Assistant Secretary
for Minority Health in improving the
health of each racial and ethnic
minority group and on the development
of goals and specific program activities
of the Office of Minority Health.
Topics to be discussed during the
meeting will include strategies to
improve the health of racial and ethnic
minority populations through the
development of health policies and
programs that will help eliminate health
disparities, as well as other related
issues.
Public attendance at this meeting is
limited to space available. Individuals
who plan to attend and need special
assistance, such as sign language
interpretation or other reasonable
accommodations, should notify the
designated contact person at least
fourteen (14) business days prior to the
meeting. Members of the public will
have an opportunity to provide
comments at the meeting. Public
comments will be limited to three
minutes per speaker. Individuals who
would like to submit written statements
should mail or fax their comments to
the Office of Minority Health at least
seven (7) business days prior to the
meeting. Any members of the public
who wish to have printed material
distributed to ACMH committee
members should submit their materials
to the Designated Federal Officer,
ACMH, Tower Building, 1101 Wootton
Parkway, Suite 600, Rockville,
Maryland 20852, prior to close of
business on Tuesday, July 14, 2015.
SUPPLEMENTARY INFORMATION:
Dated: June 23, 2015.
Rashida Dorsey,
Designated Federal Officer, ACMH, Office of
Minority Health, U.S. Department of Health
and Human Services.
[FR Doc. 2015–16195 Filed 6–30–15; 8:45 am]
BILLING CODE 4150–29–P
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
ACTION: Notice.
tkelley on DSK3SPTVN1PROD with NOTICES
AGENCY:
HHS gives notice concerning
the final effect of the HHS decision to
designate a class of employees from the
18:30 Jun 30, 2015
Jkt 235001
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
NIOSH, 1090 Tusculum Avenue, MS C–
46, Cincinnati, OH 45226–1938,
Telephone 877–222–7570. Information
requests can also be submitted by email
to DCAS@CDC.GOV.
SUPPLEMENTARY INFORMATION:
Authority: 42 U.S.C. 7384q(b). 42
U.S.C. 7384l(14)(C). On May 20, 2015,
as provided for under 42 U.S.C.
7384l(14)(C), the Secretary of HHS
designated the following class of
employees as an addition to the SEC:
All employees of the Department of
Energy, its predecessor agencies, and its
contractors and subcontractors who worked
at the Grand Junction Facilities site in Grand
Junction, Colorado, during the period from
February 1, 1975, through December 31,
1985, for a number of work days aggregating
at least 250 work days, occurring either
solely under this employment or in
combination with work days within the
parameters established for one or more other
classes of employees in the Special Exposure
Cohort.
This designation became effective on
June 19, 2015. Therefore, beginning on
June 19, 2015, members of this class of
employees, defined as reported in this
notice, became members of the SEC.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2015–16268 Filed 6–30–15; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institute for
Occupational Safety and Health
(NIOSH), Centers for Disease Control
and Prevention, Department of Health
and Human Services (HHS).
ACTION: Notice.
AGENCY:
Final Effect of Designation of a Class
of Employees for Addition to the
Special Exposure Cohort
VerDate Sep<11>2014
FOR FURTHER INFORMATION CONTACT:
Final Effect of Designation of a Class
of Employees for Addition to the
Special Exposure Cohort
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
SUMMARY:
Grand Junction Facilities site in Grand
Junction, Colorado, as an addition to the
Special Exposure Cohort (SEC) under
the Energy Employees Occupational
Illness Compensation Program Act of
2000.
HHS gives notice concerning
the final effect of the HHS decision to
designate a class of employees from the
Hanford site in Richland, Washington,
as an addition to the Special Exposure
Cohort (SEC) under the Energy
Employees Occupational Illness
Compensation Program Act of 2000.
SUMMARY:
PO 00000
Frm 00062
Fmt 4703
Sfmt 4703
37641
FOR FURTHER INFORMATION CONTACT:
Stuart L. Hinnefeld, Director, Division
of Compensation Analysis and Support,
NIOSH, 1090 Tusculum Avenue, MS C–
46, Cincinnati, OH 45226–1938,
Telephone 877–222–7570. Information
requests can also be submitted by email
to DCAS@CDC.GOV.
SUPPLEMENTARY INFORMATION:
Authority: 42 U.S.C. 7384q(b). 42 U.S.C.
7384l(14)(C).
On May 20, 2015, as provided for
under 42 U.S.C. 7384l(14)(C), the
Secretary of HHS designated the
following class of employees as an
addition to the SEC:
All employees of Department of Energy
contractors and subcontractors (excluding
employees of the following Hanford prime
contractors during the specified time periods:
Battelle Memorial Institute, January 1, 1984,
through December 31, 1990; Rockwell
Hanford Operations, January 1, 1984, through
June 28, 1987; Boeing Computer Services
Richland, January 1, 1984, through June 28,
1987; UNC Nuclear Industries, January 1,
1984, through June 28, 1987; Westinghouse
Hanford Company, January 1, 1984, through
December 31, 1990; and Hanford
Environmental Health Foundation, January 1,
1984, through December 31, 1990), who
worked at the Hanford site in Richland,
Washington, during the period from January
1, 1984, through December 31, 1990, for a
number of work days aggregating at least 250
work days, occurring either solely under this
employment, or in combination with work
days within the parameters established for
one or more other classes of employees
included in the Special Exposure Cohort.
This designation became effective on
June 21, 2015. Therefore, beginning on
June 21, 2015, members of this class of
employees, defined as reported in this
notice, became members of the SEC.
John Howard,
Director, National Institute for Occupational
Safety and Health.
[FR Doc. 2015–16277 Filed 6–30–15; 8:45 am]
BILLING CODE 4163–19–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
E:\FR\FM\01JYN1.SGM
01JYN1
37642
Federal Register / Vol. 80, No. 126 / Wednesday, July 1, 2015 / Notices
tkelley on DSK3SPTVN1PROD with NOTICES
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel;
Metabolomics Core for the Undiagnosed
Diseases Network.
Date: July 14–15, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate
cooperative agreement applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Rolf Jakobi, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6187,
MSC 7806, Bethesda, MD 20892, 301–495–
1718, jakobir@mail.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; RFA Panel:
Molecular and Cellular Substrates of
Complex Brain Disorders.
Date: July 24, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road NW.,
Washington, DC 20015.
Contact Person: Deborah L Lewis, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4183,
MSC 7850, Bethesda, MD 20892, 301–408–
9129, lewisdeb@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; National
Primate Research Centers (P51) Revision
Application.
Date: July 27, 2015.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Biao Tian, Ph.D., Scientific
Review Officer, Center for Scientific Review,
National Institutes of Health, 6701 Rockledge
Drive, Room 3089B, MSC 7848, Bethesda,
MD 20892, (301) 402–4411, tianbi@
csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cognition and Perception.
Date: July 28–29, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: Maribeth Champoux,
Ph.D., Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170,
MSC 7848, Bethesda, MD 20892, 301–594–
3163, champoum@csr.nih.gov.
VerDate Sep<11>2014
18:30 Jun 30, 2015
Jkt 235001
Name of Committee: Center for Scientific
Review Special Emphasis Panel; Member
Conflict: Cancer Immunopathology and
Immunotherapy.
Date: July 28, 2015.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Sharon K Gubanich, Ph.D.,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6195D,
MSC 7804, Bethesda, MD 20892, (301) 408–
9512, gubanics@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: June 25, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–16063 Filed 6–30–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
SUMMARY:
PO 00000
Frm 00063
Fmt 4703
Sfmt 4703
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://www.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7–
1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following HHScertified laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Dynacare, 6628 50th Street NW.,
Edmonton, AB Canada T6B 2N7, 780–
784–1190, (Formerly: GammaDynacare Medical Laboratories).
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Aegis Analytical Laboratories, Inc., 345
Hill Ave., Nashville, TN 37210, 615–
E:\FR\FM\01JYN1.SGM
01JYN1
Agencies
[Federal Register Volume 80, Number 126 (Wednesday, July 1, 2015)]
[Notices]
[Pages 37641-37642]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-16063]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose
[[Page 37642]]
confidential trade secrets or commercial property such as patentable
material, and personal information concerning individuals associated
with the grant applications, the disclosure of which would constitute a
clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Metabolomics Core for the Undiagnosed Diseases Network.
Date: July 14-15, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate cooperative agreement
applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Rolf Jakobi, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 6187, MSC 7806, Bethesda, MD 20892, 301-495-
1718, jakobir@mail.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; RFA Panel: Molecular and Cellular Substrates of Complex Brain
Disorders.
Date: July 24, 2015.
Time: 8:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant applications.
Place: Embassy Suites at the Chevy Chase Pavilion, 4300 Military
Road NW., Washington, DC 20015.
Contact Person: Deborah L Lewis, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4183, MSC 7850, Bethesda, MD
20892, 301-408-9129, lewisdeb@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; National Primate Research Centers (P51) Revision Application.
Date: July 27, 2015.
Time: 11:00 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Biao Tian, Ph.D., Scientific Review Officer,
Center for Scientific Review, National Institutes of Health, 6701
Rockledge Drive, Room 3089B, MSC 7848, Bethesda, MD 20892, (301)
402-4411, tianbi@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cognition and Perception.
Date: July 28-29, 2015.
Time: 9:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Virtual Meeting).
Contact Person: Maribeth Champoux, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3170, MSC 7848, Bethesda, MD
20892, 301-594-3163, champoum@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel; Member Conflict: Cancer Immunopathology and Immunotherapy.
Date: July 28, 2015.
Time: 1:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892, (Telephone Conference Call).
Contact Person: Sharon K Gubanich, Ph.D., Scientific Review
Officer, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6195D, MSC 7804, Bethesda, MD
20892, (301) 408-9512, gubanics@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: June 25, 2015.
Carolyn Baum,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-16063 Filed 6-30-15; 8:45 am]
BILLING CODE 4140-01-P